MedPath

Trial on Metoclopramide and Ketoprofen in Acute Migraine of Childhood

Phase 3
Withdrawn
Conditions
Migraine
Interventions
Registration Number
NCT00557544
Lead Sponsor
IRCCS Burlo Garofolo
Brief Summary

This is a Randomized double blind trial with the aim to estimate the effectiveness of 3 therapeutic regimes per os on migraine pain:

* metoclopramide 0,15 mg/kg + placebo

* metoclopramide 0,15 mg/Kg + ketoprofen 1 mg/kg

* ketoprofen 1 mg/Kg + placebo

Intensity of pain will be measured with linear 1-10 scale or analogic McGrath type scale every 20 min.

The main objective is the evaluation of healing times from pain in the 3 groups

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Children 6-17 years old with migraine presenting in emergency room
Exclusion Criteria
  • Informed consensus not obtained
  • Occurring migraine still treated
  • Hemiplegic migraine

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3ketoprofenketoprofen 1 mg/Kg and placebo in single dose
2metoclopramidemetoclopramide 0,15 mg/Kg + placebo per os
2placebometoclopramide 0,15 mg/Kg + placebo per os
3placeboketoprofen 1 mg/Kg and placebo in single dose
1ketoprofenmetoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
1metoclopramidemetoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
Primary Outcome Measures
NameTimeMethod
evaluation of healing times from pain in the 3 groups2 hours
Secondary Outcome Measures
NameTimeMethod
need of a rescue drug for lack of effect in every arms of the trial2 hours and 24 hours for relapses
comparison of percentage of healing from acute migraine and of relapses of pain in the three arms of trial2 and 24 hours respectively

Trial Locations

Locations (1)

Edoardo Guglia

🇮🇹

Trieste, Italy

© Copyright 2025. All Rights Reserved by MedPath